Regenerative Medicine

Cold chain technology deal

GE Healthcare has expanded its capacity for industralising cell therapies with the acquisition of Asymptote Ltd, a UK consultancy with technology for simplifying the freezing of cells intended as therapies, and thawing them before their use in patients.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Meeting Report: Opportunities in cell and gene therapy

The opportunities for commercialising cell and gene therapies appeared relatively bright as the first quarter drew to a close, helped by new finance and the prospective approval of the first cancer products made from engineered T cells.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Spain

Adaptimmune raises $61.8 million to progress TCR products

Adaptimmune Therapeutics Plc has raised $61.8 million, net of expenses, in a public offering of its American Depositary Shares (ADSs) to advance its T cell receptor products for cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Cell Medica raises £60 million in Series C round

Cell Medica Ltd has closed a £60 million Series C financing round to support its cell therapy platforms. The financing was announced not long after the company received a fast track designation from the US Food and Drug Administration for its lead oncology product baltaleucel-T.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Kite says rolling application to FDA finishes soon

Kite Pharma Inc has published further positive data for its lead chimeric antigen receptor (CAR) T cell therapy for cancer, while confirming that its rolling application to the FDA to receive marketing approval should be complete by the end of the first quarter.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

UCART19 cleared for trial in US

The US Food and Drug Administration has given regulatory clearance for a Phase 1 trial of Cellectis SA’s allogeneic, gene-edited cell therapy for the treatment of refractory acute lymphoblastic leukaemia (ALL). The product is being developed by Servier and Pfizer Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Case study of gene therapy

A case study of a young patient with sickle cell disease who was successfully treated with an experimental gene therapy has been published in the 2 March 2017 edition of The New England Journal of Medicine. It is believed to be the first treatment to deliver substantial relief from a disease that can sometimes lead to an early death.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

TxCell embraces the CAR

TxCell SA expects to start a clinical trial in late 2018 of a regulatory T cell product that has been engineered to contain a chimeric antigen receptor (CAR). The French company’s therapeutic focus is severe inflammatory and autoimmune diseases as well as organ transplant rejection.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Chimeric organs described

Scientists at the Salk Institute in California, US have described a series of experiments in which they were able to integrate stem cells from one species into the early-stage development of another. The research was published in the 26 January 2017 edition of Cell, and raises hopes for transplantation.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Letter from the Editor: Innovation in the New Year

(The following editorial appears in the January 2017 edition of MedNous) Yes, there are plenty of geopolitical risks going into 2017, but the biopharma industry is entering the New Year with plenty of cash and good prospects for innovation. In this issue we look at some recent developments.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Syndicate content